Semaglutide: The truth behind Wegovy, Alzheimer’s, and what no influencer tells you

If you’ve been keeping up with health trends or simply walked past a pharmacy in recent months, you’ve surely heard about semaglutide. It’s that complicated-sounding name everyone associates with the famous weight-loss pen, but trust me, the story goes far beyond mirror selfies or miracle prescriptions we see on social media. As someone who’s covered the pharmaceutical industry for years, let me tell you what’s really happening—especially after data leaked from international conferences that took the conversation in an unexpected direction.

The boom of the famous “pen” and what lies beneath

The arrival of drugs like Wegovy and Ozempic revolutionised how we view diabetes and obesity treatment. On the streets of Singapore, it’s not unusual to hear someone asking for Wegovy 0.25mg, that specific presentation that comes in a box with a pre-filled application system containing 1.5mL of solution for subcutaneous use plus 4 Novofine Plus needles. It’s the starter dose, the one many seek out to begin treatment. But here’s the first hard truth: this isn’t a toy. When I see semaglutide being sold as a magical solution to shed five kilos in a month without breaking a sweat, it makes my hair stand on end. Because it’s a potent drug, and like any potent drug, it comes with rules.

The news no one saw coming: Is the hope against Alzheimer’s fading?

A few months ago, the scientific community was buzzing with excitement. There was real hope that semaglutide wouldn’t just help with weight or blood sugar, but could also act as a shield against Alzheimer’s. Studies suggested a neuroprotective effect, hinting that it might slow cognitive decline. It was like finding an added bonus to something already working. But, as life often shows us, reality just delivered a hard check.

Just weeks ago, during the final phase III clinical trials we’d been eagerly awaiting, the conclusion was clear: semaglutide failed to slow the progression of mild Alzheimer’s. It pained me to read the internal report, because I know many families in Singapore, caring for loved ones with this disease, had pinned their hopes on it. The data, which we handle carefully within the industry, showed that while the drug works wonders on metabolism, when it comes to memory loss and cognitive function, there was simply no significant difference between those taking the drug and those on a placebo. It’s a full stop to one of the most exciting hypotheses proposed in recent years.

What you need to know if you’re already using semaglutide

That it doesn’t work for Alzheimer’s doesn’t take away from its effectiveness for what it’s approved for. But here’s where I want to get serious with you, because from my experience, people tend to skip the steps. If you’re considering using Wegovy 0.25mg or any form of it, keep this in mind:

• It’s not for everyone: The initial 0.25mg dose is designed to help your body adjust. Skipping doses or starting with a higher one could land you straight in hospital with pancreatitis.
• The application system isn’t optional: That “pre-filled application system with 1.5mL of subcutaneous solution” isn’t just for show. The way it’s administered and the Novofine Plus needles are designed to minimise pain and ensure the dose is accurate.
• It’s a treatment, not a one-month fad: Semaglutide works while you’re on it. I’ve seen cases of people using it for an event and then stopping, only to regain the weight—and then some. This is a long-term commitment, if your doctor determines it’s right for you.

The “Singapore” factor and the grey market

Here in Singapore, we have a very particular relationship with medication. Self-prescribing and the idea of getting “just a little bit” is common. With semaglutide, it’s been chaos. I’ve seen WhatsApp groups sharing sellers offering “generic Wegovy” or the “diabetic version” as if they were candy. I’m telling you with the confidence of someone who’s seen both sides of the coin: don’t take the risk. The Novofine Plus needles that come in the official box aren’t a luxury; they’re part of a safety protocol. Buying this on the informal market is playing Russian roulette with your health.

The failure of studies to stop Alzheimer’s isn’t bad news per se, but rather an invitation to get grounded in reality. Science moves forward, sometimes with setbacks, but it keeps moving. Semaglutide is an incredibly useful tool for those who truly need it under medical supervision. For everyone else, the lesson is clear: don’t look for shortcuts, especially when it comes to your brain and your well-being. If your doctor prescribed it, trust the process, respect the dosages, and follow the subcutaneous application system. If you’re only after it because it’s trendy, maybe it’s time to sit down and think about whether it’s worth playing with fire.